Comparative Pharmacology
Head-to-head clinical analysis: PERIACTIN versus PROMETH PLAIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PERIACTIN versus PROMETH PLAIN.
PERIACTIN vs PROMETH PLAIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyproheptadine is a first-generation antihistamine with anticholinergic and antiserotonergic properties. It acts as a competitive antagonist at histamine H1 receptors and serotonin 5-HT2 receptors, thereby inhibiting histamine-mediated allergic symptoms and serotonin-mediated effects such as increased gastrointestinal motility and vascular permeability.
Antagonist at histamine H1 receptors; also exhibits anticholinergic, antiemetic, and sedative effects.
4 mg orally three times daily; adjust as needed. Maximum: 32 mg/day.
12.5-25 mg intramuscularly or intravenously every 4-6 hours as needed; maximum 100 mg/day.
None Documented
None Documented
10-12 hours terminal elimination half-life; steady-state reached in 2-3 days
Terminal elimination half-life is 10-14 hours in adults; may be prolonged in elderly or hepatic impairment.
Renal (40-50% as metabolites, <5% unchanged); biliary/fecal (minor, ~10-20%)
Primarily renal (approximately 70%) as metabolites and unchanged drug; biliary/fecal excretion accounts for ~20%.
Category C
Category C
Antihistamine
Antihistamine